Farzin Haque
Stock Analyst at Jefferies
(2.74)
# 2,913
Out of 4,673 analysts
11
Total ratings
54.5%
Success rate
10%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Initiated Coverage: Buy | $50 | $23.36 | +114.04% | 1 | Mar 29, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $9 | $4.63 | +94.38% | 1 | Dec 21, 2025 | |
| VERA Vera Therapeutics | Maintained: Buy | $57 → $45 | $32.28 | +39.43% | 4 | Nov 26, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgraded: Buy | $42 | $45.89 | -8.48% | 1 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $10 | $6.93 | +44.30% | 1 | Sep 29, 2025 | |
| HOWL Werewolf Therapeutics | Initiated Coverage: Buy | $4 | $0.8735 | n/a | 1 | Aug 4, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $10 → $6 | $3.08 | n/a | 2 | Mar 18, 2025 |
Vor Biopharma
Mar 29, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $23.36
Upside: +114.04%
Relmada Therapeutics
Dec 21, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $4.63
Upside: +94.38%
Vera Therapeutics
Nov 26, 2025
Maintained: Buy
Price Target: $57 → $45
Current: $32.28
Upside: +39.43%
Rigel Pharmaceuticals
Nov 5, 2025
Upgraded: Buy
Price Target: $42
Current: $45.89
Upside: -8.48%
Nuvation Bio
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $6.93
Upside: +44.30%
Werewolf Therapeutics
Aug 4, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $0.8735
Upside: n/a
Pyxis Oncology
Mar 18, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $3.08
Upside: n/a